Advertisement

Familial Cancer

, Volume 17, Issue 2, pp 255–259 | Cite as

Pancreatic adenocarcinoma with a germline PTEN p.Arg234Gln mutation

  • Sunao Uemura
  • Hiroyuki Matsubayashi
  • Yoshimi Kiyozumi
  • Katsuhiko Uesaka
  • Yusuke Yamamoto
  • Keiko Sasaki
  • Masato Abe
  • Kenichi Urakami
  • Masatoshi Kusuhara
  • Ken Yamaguchi
Short Communication

Abstract

A minor fraction of pancreatic ductal adenocarcinoma (PDAC) develops in association with germline mutations of the genes responsible for inherited cancer syndromes. However, the PDAC that has a germline PTEN mutation has not received much attention. Genome-wide whole exome sequencing was performed on germline and somatic DNA from an 82-year-old woman who had developed a solid pancreatic cancer but did not show characteristic findings of PTEN hamartoma tumor syndromes (PHTS). Histology of the resected pancreatic tumor showed unique PDAC findings of primarily dendriform structures and dense fibrous tissue, accompanied by multiple pancreatic intraepithelial neoplasias in the vicinity. The tumor immunohistochemistry revealed a loss of PTEN expression and overexpression of TP53. Exome sequencing revealed a K-ras mutation (p.Gly12Val). Germline exome sequencing revealed a missense mutation of PTEN (p.Arg234Gln), a rare variant with a reported association with cancer development but not with other PHTS phenotypes. To our knowledge, this is the first report of PDAC associated with a germline PTEN mutation, particularly a rare variant (p.Arg234Gln) with cancer risks.

Keywords

Pancreas Adenocarcinoma PTEN p.Arg234Gln (R234Q) Germline mutation 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Institutional Review Board of Shizuoka Cancer Center (Institutional code number: 27-33-27-4-5) ethically approved this study.

Informed consent

Written informed consent on the study and permission for the case report publication was obtained from the patient.

Supplementary material

10689_2017_25_MOESM1_ESM.pptx (61 kb)
Supplementary material 1 (PPTX 61 KB)

References

  1. 1.
    Eng C (2014) PTEN Hamartoma Tumor Syndrome (PHTS): GeneReviews [Internet] http://www.ncbi.nlm.nih.gov/books/NBK1488/
  2. 2.
    Spinelli L, Black FM, Berg JN et al (2015) Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes. J Med Genet 52:128–134CrossRefPubMedGoogle Scholar
  3. 3.
    Salmena L, Carracedo A, Pandolfi PP (2008) Tenets of PTEN tumor suppression. Cell 133:403–414CrossRefPubMedGoogle Scholar
  4. 4.
    Ying H, Elpek KG, Vinjamoori A et al (2011) PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaB-cytokine network. Cancer Discov 1:158–169CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Urakami K, Shimoda Y, Ohshima K et al (2016) Next generation sequencing approach for detecting 491 fusion genes from human cancer. Biomed Res 37:51–62CrossRefPubMedGoogle Scholar
  6. 6.
    Staal FJ, van der Luijt RB, Baert MR et al (2002) A novel germline mutation of PTEN associated with brain tumours of multiple lineages. Br J Cancer 86:1586–1591CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Marsh DJ, Dahia PL, Coulon V et al (1998) Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. Genes Chromosomes Cancer 21:61–69CrossRefPubMedGoogle Scholar
  8. 8.
    Caserta E, Egriboz O, Wang H et al (2015) Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo. Genes Dev 29:1707–1720CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Smyrk TC, Watson P, Kaul K et al (2001) Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 91:2417–2422CrossRefPubMedGoogle Scholar
  10. 10.
    Nose V (2011) Familial thyroid cancer: a review. Mod Pathol 24(Suppl 2):S19–S33CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  • Sunao Uemura
    • 1
    • 2
  • Hiroyuki Matsubayashi
    • 3
    • 4
  • Yoshimi Kiyozumi
    • 3
  • Katsuhiko Uesaka
    • 2
  • Yusuke Yamamoto
    • 2
  • Keiko Sasaki
    • 1
  • Masato Abe
    • 1
  • Kenichi Urakami
    • 5
  • Masatoshi Kusuhara
    • 5
  • Ken Yamaguchi
    • 5
  1. 1.Division of PathologyShizuoka Cancer CenterNagaizumiJapan
  2. 2.Division of Hepato-Biliary-Pancreatic SurgeryShizuoka Cancer CenterNagaizumiJapan
  3. 3.Familial Cancer ClinicShizuoka Cancer CenterNagaizumiJapan
  4. 4.Division of EndoscopyShizuoka Cancer CenterNagaizumiJapan
  5. 5.Research Institution of Shizuoka Cancer CenterNagaizumiJapan

Personalised recommendations